The source of Chinese medicine, Akolading: New progress has been made in the study of the mechanism of anti-tumor action of small molecule immunomodulation

Acolatin is a new class 1 Chinese medicine in clinical Phase III study conducted by Beijing Shengnoki Pharmaceuticals, and previous studies have shown that Acolatin, as a small molecule extracted from Chinese medicine, has anti-inflammatory, direct inhibition of tumor cell growth and anti-tumor cell growth immunomodulation.
the European Journal of Immunology published a paper on Acolating's regulation of PD-L1 on the cover of issue 12 of 2019.
NF-KB is the key factor of the most important signaling path through biological immune responses such as apoptosis, anti-inflammation and anti-infection, while the activity and migration of NF-KB is fine-tuned by complex molecules such as IKK.
The Beijing Shengnoki team and relevant medical research units cooperated in the application of biochemical methods combined with molecular target high-volume screening technology, and found that Acolatin can directly act on the NF-KB signaling path, IKK alpha, IKK beta, interfere with the production of IKK kinase complex, inhibit NF-KB migration from the cytokine to the nucleus, thereby reducing the expression of the immune checkpoint ligation molecule PD-L1.
The study provides an important molecular biological basis for further study of Acolatin's anti-inflammatory and immunomodulation signaling path, anti-tumor mechanism and combination drug use, and is expected to provide more innovative ideas and options for clinical research on the unique immunomodulation and joint treatment of tumor patients by Acolatin, a small molecule of Chinese medicine.
。